Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708640 | 1.00 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL16568536 | 0.93 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL8773395 | 0.93 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL15305567 | 0.89 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL860823 | 0.89 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL20515185 | 0.88 | TLR8 (0.67) | TLR7TLR8 | |
| SCHEMBL28627809 | 0.88 | TLR8 (0.67) | TLR7TLR8 | |
| SCHEMBL4201925 | 0.88 | TLR7 (0.87) | TLR7TLR8 | |
| SCHEMBL4201920 | 0.88 | TLR7 (0.87) | TLR7TLR8 | |
| SCHEMBL8818268 | 0.87 | TLR7 (0.77) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440560-B2 | Substituted pyrimidines as vaccine adjuvants | Sumitomo Pharma Co., Ltd. (JP) | 2025-10-14 | — | — | US | disclosed |
| EP-3603619-B1 | VACCINE ADJUVANT FORMULATION | SUMITOMO PHARMA CO LTD (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20240245766-A1 | PYRIMIDINE COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-25 | — | — | US | disclosed |
| US-11911466-B2 | Substituted pyrimidines as vaccine adjuvants | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11833247-B2 | Vaccine adjuvant formulation | Sumitomo Pharma Co., Ltd. (JP) | 2023-12-05 | — | — | US | disclosed |
| EP-3868741-B1 | COMPOSITION COMPRISING A PYRIMIDINE COMPOUND AND A PATHOGEN DERIVED ANTIGEN | SUMITOMO PHARMA CO LTD (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-20220273563-A1 | VACCINE ADJUVANT FORMULATION | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-01 | — | — | US | disclosed |
| US-20220226468-A1 | PYRIMIDINE COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-21 | — | — | US | disclosed |
| US-11253476-B2 | Vaccine adjuvant formulation | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-02-22 | — | — | US | disclosed |
| CN-108290845-B | Pyrimidine compounds | 大日本住友制药株式会社 | 2021-08-03 | — | — | CN | disclosed |
| US-20200121600-A1 | VACCINE ADJUVANT FORMULATION | Sumitomo Pharma Co., Ltd. (JP) | 2020-04-23 | — | — | US | disclosed |
| EP-3603619-A1 | VACCINE ADJUVANT FORMULATION | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110650729-A | Vaccine adjuvant formulations | 大日本住友制药株式会社 | 2020-01-03 | — | — | CN | disclosed |
| US-20180280499-A1 | PYRIMIDINE COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-2432768-B1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9533978-B2 | Pyrimidine derivatives and their use in the treatment of cancer and further diseases | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA UK LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833247-B2 | Vaccine adjuvant formulation | TLR7, TLR9, TLR5 | TLR7 1/4885TLR8 4/4885 |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | TYMS, TYMP, DPYD | TLR7 2123/4885TLR8 4294/4885 |
| US-20240245766-A1 | PYRIMIDINE COMPOUND | TYMS, TYMP, DPYD | TLR7 61/4885TLR8 731/4885 |
| US-20220273563-A1 | VACCINE ADJUVANT FORMULATION | TLR7, TLR9, TLR5 | TLR7 1/4885TLR8 4/4885 |
| US-20220226468-A1 | PYRIMIDINE COMPOUND | TYMS, TYMP, DPYD | TLR7 61/4885TLR8 731/4885 |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | TYMS, TYMP, DPYD | TLR7 2123/4885TLR8 4294/4885 |
| US-11253476-B2 | Vaccine adjuvant formulation | TLR7, TLR9, TLR5 | TLR7 1/4885TLR8 4/4885 |
| US-20200121600-A1 | VACCINE ADJUVANT FORMULATION | TLR7, TLR9, TLR5 | TLR7 1/4885TLR8 4/4885 |
| US-11911466-B2 | Substituted pyrimidines as vaccine adjuvants | TYMS, UMPS, P2RY1 | TLR7 21/4885TLR8 300/4885 |
| US-20180280499-A1 | PYRIMIDINE COMPOUND | TYMS, TYMP, DPYD | TLR7 61/4885TLR8 731/4885 |
| US-12440560-B2 | Substituted pyrimidines as vaccine adjuvants | TYMS, UMPS, P2RY1 | TLR7 21/4885TLR8 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.